Crossmark

The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised, controlled trial

Crossref DOI link: https://doi.org/10.1007/s00125-020-05306-1

Published Online: 2020-10-16

Published Print: 2021-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Færch, Kristine https://orcid.org/0000-0002-6127-0448
Blond, Martin B. https://orcid.org/0000-0002-2032-1560
Bruhn, Lea https://orcid.org/0000-0002-5945-765X
Amadid, Hanan https://orcid.org/0000-0001-5759-4960
Vistisen, Dorte https://orcid.org/0000-0001-5045-5351
Clemmensen, Kim K. B. https://orcid.org/0000-0002-4530-1945
Vainø, Camilla T. R. https://orcid.org/0000-0002-3698-4078
Pedersen, Camilla https://orcid.org/0000-0001-5507-1752
Tvermosegaard, Maria https://orcid.org/0000-0002-4585-2042
Dejgaard, Thomas F. https://orcid.org/0000-0002-0097-7052
Karstoft, Kristian https://orcid.org/0000-0002-6596-4199
Ried-Larsen, Mathias https://orcid.org/0000-0002-8388-5291
Persson, Frederik https://orcid.org/0000-0001-6242-6638
Jørgensen, Marit E. https://orcid.org/0000-0001-8356-5565
Funding

Funding for this research was provided by:

Novo Nordisk Fonden

AstraZeneca

Innovationsfonden

Det Sundhedsvidenskabelige Fakultet, Københavns Universitet

Ascensia Diabetes Care Denmark ApS
License Information

Text and Data Mining valid from 2020-10-16

Version of Record valid from 2020-10-16
More Information

Article History

Received: 22 May 2020

Accepted: 28 August 2020

First Online: 16 October 2020

Free to read: This content has been made available to all.

Document is current

Any future updates will be listed below